NAD+ and NMN are not competitors. They're the same molecule at different stages. NMN (nicotinamide mononucleotide) is converted to NAD+ inside cells by the enzyme NMNAT. The question researchers debate is whether it's better to provide the finished product (NAD+) or the raw material (NMN) and let cells do the conversion.

It sounds simple. It isn't.

Most published NAD+ aging studies have used NMN rather than NAD+ directly. The landmark studies — Gomes 2013 in Cell, Zhang 2016 in Science, Mills 2016 in Cell Metabolism — all administered NMN to aged mice and measured NAD+ level increases in target tissues.¹

The rationale: NMN is a smaller molecule (334 Da vs 663 Da) that may cross cell membranes more efficiently. In 2019, researchers identified Slc12a8, a specific NMN transporter on cell membranes, providing a molecular mechanism for direct NMN uptake into cells. Once inside, NMNAT enzymes rapidly convert NMN to NAD+.²

The NMN approach has generated the most extensive published evidence base for NAD+ repletion in aging models. If you're replicating published protocols, most of them used NMN.

Direct NAD+ supplementation bypasses the NMNAT conversion step entirely. The active coenzyme is delivered without relying on enzymatic conversion that may be impaired in aged or diseased tissues — a meaningful consideration, since NMNAT activity can vary between tissue types and age groups.³

Research has shown that NAD+ can be taken up by cells through CD73-mediated dephosphorylation at the cell surface (NAD+ → NMN → NR → cell entry → reconversion to NAD+) and potentially through direct transport mechanisms that are still being characterized.

The direct approach is particularly relevant for in vitro research, where NAD+ can be added to cell culture media without any absorption or transport barriers. For cell-based assays, direct NAD+ supplementation provides precise control over the coenzyme concentration reaching the cells.

OSYRIS offers NAD+ in its active form specifically for research protocols that require the finished coenzyme rather than a precursor.

The honest assessment: most of the dramatic aging results come from NMN studies, not direct NAD+ studies. This doesn't mean NMN is superior — it means NMN has been more extensively studied in this context. The evidence gap reflects research history rather than a proven biological difference.

A few direct NAD+ administration studies exist, primarily using intravenous or intraperitoneal delivery in animal models, showing tissue NAD+ level increases and functional improvements consistent with the NMN literature. But the body of evidence is smaller.⁴

The field is moving toward a more nuanced understanding: the optimal NAD+ repletion strategy may depend on the tissue type, the delivery route, and the specific research question. Cell culture studies may favor direct NAD+. In vivo studies with oral delivery may favor NMN. Neither approach is universally superior.

Nicotinamide riboside (NR) is another NAD+ precursor, one step further upstream than NMN in the salvage pathway (NR → NMN → NAD+). NR has its own body of published evidence, including human clinical trials showing blood NAD+ increases. NR is not currently in the OSYRIS catalog.⁵

OSYRIS offers the active coenzyme rather than a precursor for several reasons: it eliminates conversion-step variability in research protocols, it provides exact concentration control in cell culture, and it serves researchers studying NAD+ biology directly (sirtuin activation assays, PARP activity assays, electron transport chain studies) where the active molecule is the appropriate reagent.

For researchers who specifically need NMN for protocols replicating published NMN studies, NMN is widely available from other suppliers. OSYRIS fills the gap for research-grade direct NAD+ with batch-specific independent testing.